Related Experiment Video
Updated: Mar 16, 2026

A Metadata Extraction Approach for Clinical Case Reports to Enable Advanced Understanding of Biomedical Concepts
Published on: September 20, 2018
Clinical spectrum and outcomes of crescentic glomerulonephritis: A single center experience
S K Rampelli1, N G Rajesh2, B H Srinivas2
1Department of Medicine, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
Insights
Crescentic glomerulonephritis (CrGN) in India predominantly stems from immune-complex glomerulonephritis (ICGN). Outcomes are poor, with most patients progressing to end-stage renal disease or death, highlighting a need for better management strategies.
Area of Science:
- Nephrology
- Immunology
- Pathology
Background:
- Limited data exists on crescentic glomerulonephritis (CrGN) in the adult Indian population.
- Understanding the etiology, clinical presentation, and outcomes of CrGN is crucial for improving patient care.
Purpose of the Study:
- To prospectively evaluate the etiology, clinicohistological patterns, and predictors of outcome for CrGN in South India.
- To identify factors associated with adverse outcomes in CrGN patients.
Main Methods:
- Prospective study of adult CrGN patients receiving standard immunosuppression and supportive care.
- Etiological classification into immune-complex glomerulonephritis (ICGN), pauci-immune glomerulonephritis (PauciGN), and anti-glomerular basement membrane disease.
- Histopathological analysis and 3-month follow-up for clinical outcomes and survival.
Main Results:
- Immune-complex glomerulonephritis (ICGN) was the most common etiology (77.5%), followed by pauci-immune glomerulonephritis (PauciGN) (20%).
- IgA nephropathy, lupus nephritis, and post-infectious glomerulonephritis (PIGN) were the leading causes of ICGN.
- High rates of end-stage renal failure (48.6%) and mortality (18.9%) were observed within 3 months; complete remission was rare (5.4%).
- Hypertension, need for renal replacement therapy, admission serum creatinine, estimated glomerular filtration rate, and percentage of fibrocellular crescents predicted adverse outcomes.
Conclusions:
- CrGN in South India is primarily caused by ICGN, with significant morbidity and mortality.
- Predictors of adverse outcomes include hypertension, need for RRT, and specific histopathological findings.
- Further research is needed to improve treatment strategies and outcomes for CrGN patients in this population.
Abstract:
There is limited data on the etiology, clinical and histopathological spectrum and outcomes of crescentic glomerulonephritis (CrGN) in adult Indian population. This prospective study was done to evaluate the etiology, clinicohistological patterns and predictors of outcome of CrGN in South Indian population. All the patients received standard protocol based immunosuppression in addition to supportive care. Immune-complex glomerulonephritis (ICGN) was the most common etiology (n = 31; 77.5%) followed by pauci-immune glomerulonephritis (PauciGN; n = 8; 20%) and anti-glomerular basement membrane disease (n = 1; 2.5%). The most common etiology of ICGN was IgA nephropathy (n = 11; 27.5%) followed by lupus nephritis (n = 7; 17.5%) and post-infectious glomerulonephritis (PIGN) (n = 7; 17.5%). The patients with PauciGN were significantly older compared to those with ICGN (44.5 ± 15 years vs. 31.8 ± 11 years; P = 0.01). The patients with PauciGN presented with significantly higher serum creatinine (9.7 ± 4.4 vs. 6.6 ± 3.3 mg/dl; P = 0.03). The histopathologic parameters of ICGN and PauciGN were comparable except for a higher proportion of sclerosed glomeruli in ICGN. At the end of 3 months follow-up, only two patients went into complete remission (5.4%). Majority of the patients had end-stage renal failure (48.6%) and were dialysis dependent and seven patients (18.9%) expired. There was no signifi difference in the renal survival (10.9 ± 1.9 vs. 9.6 ± 3.3 months) or patient survival (17.5 ± 2.1 vs. 17.3 ± 4.3 months). The parameters associated with adverse outcomes at 3 months were hypertension (odds ratio [OR]: 0.58; confidence interval [CI]: 0.36-0.94), need for renal replacement therapy (OR: 0.19; CI: 0.04-0.9), serum creatinine at admission (P = 0.019), estimated glomerular filtration rate (P = 0.022) and percentage of fibrocellular crescents (P = 0.022).
More Related Videos
06:39Glomerular Outgrowth as an Ex Vivo Assay to Analyze Pathways Involved in Parietal Epithelial Cell Activation
Published on: August 19, 2020
09:43Analyses of Proteinuria, Renal Infiltration of Leukocytes, and Renal Deposition of Proteins in Lupus-prone MRL/lpr Mice
Published on: June 8, 2022
Related Concept Videos
Nephrotic Syndrome I : Introduction
Acute Pyelonephritis II: Diagnostic Studies and Management
Acute Pyelonephritis I: Introduction
Acute Kidney Injury III: Clinical Manifestations
Nephrotic Syndrome II : Assessment and Medical Management
Endocarditis II: Clinical Features of Infective Endocarditis